Overexpression of Stimulatory G Protein Alpha-subunit Is a Hallmark of Most Human Somatotrophic Pituitary Tumours and Is Associated with Resistance to GH-releasing Hormone

Pituitary

Volumn 1, Issue 1, 1998, Pages 13-23

  Hamacher, Christiane ^a   Bröcker, Martina ^a   Adams, Eric Frank ^b   Lei, Ting ^b   Fahlbusch, Rudolf ^b   Buchfelder, Michael ^b   Derwahl, Michael ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

G protein; GH; GHRH; Pituitary

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; ADENYLATE CYCLASE; GROWTH HORMONE RELEASING FACTOR; HUMAN GROWTH HORMONE; ONCOPROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ADENOMA; ADOLESCENT; ADULT; AGED; ARTICLE; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; METABOLISM; MIDDLE AGED; ONCOGENE; SECRETION;

ADENOMA; ADENOSINE DIPHOSPHATE RIBOSE; ADENYLATE CYCLASE; ADOLESCENT; ADULT; AGED; DRUG RESISTANCE; FEMALE; GROWTH HORMONE-RELEASING HORMONE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMAN GROWTH HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ONCOGENE PROTEINS; ONCOGENES; PITUITARY NEOPLASMS;

EID: 0032034458     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009910623127     Document Type: Article

References (33)

1. Gordeladze JO, Johansen PW, Paulssen RH, Gautvik KM. G-proteins: Implications for pathophysiology and disease. Eur J Endocrinol 1994;131:557-574.
2. Faglia G. Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinol 1993;129(Suppl):1-5.
3. Levine MA, Jap TS, Mauseth RS, Downs RW, Spiegel AM. Activity of the stimulatory guanine nucleotide-binding protein is reduced in erythrocytes from patients with pseudohypoparathyroidism; biochemical, endocrine and genetic analysis of Albright's hereditary osteodystrophy in six kindreds. J Clin Endocrinol Metab 1986;62:497-500.
4. Patten JL, Levine MA. Immunological analyses of the alpha-subunit of the stimulatory G-protein of adenylyl cyclase in patients with Albright's hereditary dystrophy. J Clin Endocrinol Metab 1990;71-08-1214.
5. s and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987;330:566-568.
6. s and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989;340:692-696.
7. Adams EF, Brockmeier S, Friedman E, Roth M, Buchfelder M, Fahlbusch R. Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery 1993;33:198-203.
8. Adams EF, Lei T, Buchfelder M, Petersen B, Fahlbusch R. Biochemical characteristics of human pituitary somatotrophinomas with and without gsp mutations: In vitro cell culture studies. J Clin Endocrinol Metab 1995;80:2077-2081.
9. Siperstein AE, Miller RA, Landis C, Bourne HR, Clarke OH. Increased stimualtory G protein in neoplastic human thyroid tissues. Surgery 1991;110:949-955.
10. s-alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. J Clin Endocrinol Metab 1996;1:1898-1904.
11. s alpha-identification of a gene highly expressed by insulinoma and other endocrine tissues. Surgery 1993;114:458-463.
12. Hamacher C, Studer H, Zbaeren J, Schatz H, Derwahl M. Expression of functional stimulatory guanine nucleotide binding protein in nonfunctioning thyroid adenomas is not correlated to adenylate cyclase activity and growth of these tumors. J Clin Metab 1995;80:1724-1732.
13. Bertherat J, Chanson P, Montminy M. The cyclic adenosine 3′, 5′-monophosphate factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 1995;9:777-783.
14. Lei T, Buchfelder M, Fahlbusch R, Adams EF. Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. J Endocrinol 1995;14:135-138.
15. Adams EF, Lei T, Buchfelder M, Bowers CY, Fahlbusch R. Protein kinase C-dependent growth hormone releasing peptides stimulate cyclic adenosine 3′, 5′-monophosphate production by human pituitary somatotrophinomas expressing gsp oncogenes: Evidence for cross-talk between transduction pathways. Mol Endocrinol 1996;10:432-438.
16. Howard A, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJS, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LHT. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974-977.
17. Adams EF, Mashiter, K. Role of cell and explant culture in the diagnosis and characterisation of human pituitary tumours. Neurosurg Rev 1985;8:135-140.
18. Studer H, Gerber H, Zbären J, Peter HJ. Histomorphological and immunohistochemical evidence that human nodular goiters grow by episodic replication of multiple clusters of thyroid follicular cells. J Clin Endocrinol Metab 1992;75: 1151-1158.
19. McKenzie FR. Plasma membrane production. In: Milligan G, ed. Signal Transduction: A Practical Approach. Oxford: IRL Press, 1992; 33-34.
20. 2+. Mol Endocrinol 1987;1:473-481.
21. Johnson RA, Salomon X. Assay of adenylyl cyclase activity. Methods Enzymol 1991;195:3-21.
22. Downs RW, Levine MA, Drezner MK, Burch WM, Spiegel AM. Deficient adenylate cyclase regulatory protein in renal membranes from a patient with pseudohypoparathyroidism. J Clin Invest 1983;71:231-235.
23. Gilman AG. G proteins: Transducers of receptor-generated signals. Annu Rev Biochem 1987;56:615-649.
24. Johnson GL, Kaslow HR, Bourne HR. Reconstitution of cholera toxin-activated adenylate cyclase. Proc Natl Acad Sci USA 1978;75:3113-3117.
25. s-alpha mutants associated with human pituitary tumors: Stimulation of adenosine 3′,5′,-rnonphosphate response element-binding protein-mediated transcription and of prolactin and growth hormone promoter activity via protein kinase A. Endocrinology 1995;136:4331-4338.
26. Burton FH, Hasel KW, Bloom FE, Sutcliffe JG. Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene. Nature 1991;350:74-77.
27. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner MO. Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80: 3395-3402.
28. i alpha-2. J Biol Chem 1990;265:14784-14790.
29. Hadcock JR, Port JD, Malbon CC. Cross-regulation between G-protein-mediated pathways. Activation of inhibitory pathways of adenylyl cyclase increases the expression of beta 2-adrenergic receptors. J Biol Chem 1991;266: 11915-11922.
30. Adams EF, Bhuttacharji SC, Halliwell CLJ, Loizou M, Birch G, Mashiter K. Effect of pancreatic growth hormone releasing factors on GH secretion by human somatotrophic pituitary tumours in cell culture. Clin Endocrinol 1984;21: 709-718.
31. Wood SM, Ch'ng JL, Adams, EF, Webster JD, Joplin GF, Mashiter K, Bloom SR. Abnormalities of growth hormone release in response to human pancreatic growth hormone releasing factor (GRF(1-44)) in acromegaly and hypopituitarism. Br Med J 1983;286:1687-1691.
32. White MC, Daniels M, Kendall-Taylor P, Turner SJ, Mathias D, Teasdale G. Effects of growth hormone-releasing hormone (1-44) on growth hormone release from human somatotrophinomas in vitro: Interaction with somatostatin, dopamine, vasoactive intestinal peptide and cycloheximide. J Endocrinol 1985;105:269-276.
33. Renner U, Brockmeier S, Strasburger CJ, Lange M, Schopohl J, Müller OA, von Werder K, Satlla K. Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: Interaction with GH-releasing hormone, thyrotrophin-releasing hormone, and octreotide. J Clin Endocrinol Metab 1994;78:1090-1096.